EP1709034A2 - Procede ameliore de synthese du losartan potassique - Google Patents

Procede ameliore de synthese du losartan potassique

Info

Publication number
EP1709034A2
EP1709034A2 EP04785921A EP04785921A EP1709034A2 EP 1709034 A2 EP1709034 A2 EP 1709034A2 EP 04785921 A EP04785921 A EP 04785921A EP 04785921 A EP04785921 A EP 04785921A EP 1709034 A2 EP1709034 A2 EP 1709034A2
Authority
EP
European Patent Office
Prior art keywords
potassium
losartan
losartan potassium
methanol
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04785921A
Other languages
German (de)
English (en)
Inventor
Ashok Kumar
Rajesh Kumar Keshava Prasad Singh
Nalinakshya Balaram Panda
Abhay Atmaram Upare
Manmohan Madhavrao Nimbalkar
Satish Rajanikant Soudagar
Ashvini Kumar Nand Kishore Saxena
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipca Laboratories Ltd
Original Assignee
Ipca Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipca Laboratories Ltd filed Critical Ipca Laboratories Ltd
Publication of EP1709034A2 publication Critical patent/EP1709034A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Definitions

  • This invention relates to improvement in process for preparation of Losartan Potassium as claimed in our main application. More specifically this invention relates to a commercial process for preparation of the polymorphic Form I of Losartan potassium and an improvement in use of reagent in the reaction and conditions thereof for the preparation of the said Losartan Potassium as claimed in our main application as above.
  • Losartan potassium plays an effective role in patients having difficulty in tolerating ACE inhibitors.
  • the chemical name of Losartan potassium is 2-n-Butyl-4- Chloro- 1 - [((2 ' -tetrazol-5 -yl)-l , 1 ' -bisphenyl-4-y l)methyl] -imidazole-5 -methanol potassium.
  • Losartan potassium (shown as the compound of Formula (I) below) is known in the art is synthesized by reacting its acid (shown as the compound of formula (II) below) with KOH.
  • the intermediate acid Formula (II) in turn is synthesized by detritylation of 2- n-butyl-4-chloro-5-hydroxymethyl-l-[((2'-triphenylmethyltetrazole-5-yl) biphenyl-4-yl) methyl] imidazole (shown as the compound of Formula (III) below)
  • Trityl Losartan (the reactant of Formula (III) below) is known in the art. See 34 J. MED. CHEM. 2525-27 (1991); 59 J. ORG. CHEM. 6391-94 (1994); US 5,138,069. Trityl Losartan (and the Losartan acid/free Losartan) and may alternatively be prepared using the reactions and techniques described in US Patent 5,138,069 and patent application number W093/10106.
  • Trityl Losartan the reactant of Formula (III) of Losartan acid (II) by acid-catalyzed cleavage of trityl group from Trityl Losartan (III) is disclosed in US 5,281,603.
  • Another method disclosed to prepare Losartan acid from trityl Losartan is disclosed in US 5,281,604.
  • Trityl Losartan (III) is refluxed in a mixture of methanol and tetrahydrofuran in presence of catalytic acid like hydrochloric acid for 18 hours to get Losartan acid (II).
  • Patent application number WO98/18787 describes a method, which also starts with a solution of Losartan Potassium (I) in aqueous isopropyl alcohol and is heated to distill out water-isopropyl alcohol mixture to lower the water content to 2.6%. Further excessive seeding is carried out with slurry of Losartan Potassium (I) in cyclohexane until the seed remains undissolved. The Precipitation of the product is then achieved by continuous distillation of ternary azeotrope with simultaneous addition of cyclohexane to the reaction mass. This azeotrope distillation is carried out until moisture level decreases to about 0.2 to 0.11%. The crystallized product thus obtained is filtered.
  • the present invention avoids the use of stringent azeotropic distillation of water from the reaction mass to precipitate Losartan potassium. Also it avoids the use of antisolvents for the removal of water or for the precipitation of Losartan teachingassium as taught by the prior art.
  • the Richter Gedeon approach was found to be easy and superior to the existing methods, however was found to suffer from various drawbacks as summarized below: a) The product obtained does not pass desired solubility in various solvents. To make the product improve in quality, it needs an extra purification as per the Richter Gedeon application. b) Purification step in the process, the resultant purity and the yields thereof, depends on very precise ratios of solvent mixture (e.g. methanol, cyclohexane or acetonitrile). c) High volume of solvents and that too in very precise combination in purification which leads to capacity reduction of plant production/facilities.
  • solvent mixture e.g. methanol, cyclohexane or acetonitrile
  • Patent application number WO 02/094816 discloses use of acetone, ethyl acetate, acetonitrile and toluene as anti-solvents and has similar problems of recovery and reuse of solvents and high cost of production. Since isolation of the product is simply by precipitation using anti solvents, the product needs further purification to pass the required tests, in this case also.
  • polymorphic Form I is the addition of aqueous solution of (I) to a refluxing mixture of cyclohexane and isopropyl alcohol followed by azeotropically distilling out cyclohexane /isopropyl alcohol/water ternary azeotrope at 64°C while the Form I crystallizes out at 69°C.
  • FIG. 1 Powder X-Ray Diffraction (PXRD) pattern of Losartan potassium Form I produced from Tetra ydrofuran as solvent.
  • Figure 2. Powder X-Ray Diffraction (PXRD) pattern of Losartan potassium Form I produced from Isopropyl alcohol as solvent.
  • Figure 3. Differential Scanning Calorimeter (DSC) thermogram of Losartan potassium Form I produced from Tetrahydrofuran as solvent.
  • Figure5. FTIR spectrum of Losartan potassium Form I produced from Tetrahydrofuran as solvent from 1150 cm “1 to 600 cm “1 .
  • Figure 6. FTIR spectrum of Losartan potassium Form I produced from Tetrahydrofuran as solvent from 1800 cm “1 to 1150 cm “1 .
  • the present invention relates to an improvement in the user friendly use of the reagent in reaction and the reaction conditions for the preparation of Losartan Potassium as claimed in our main application as mentioned above. Additionally it provides process for preparation of polymorphic Form I of Losartan potassium.
  • the primary reagent in this invention is potassium tertiary butoxide, which is hygroscopic, air sensitive and a fluffy powder. To avoid contact with moisture, the operation using pure dry potassium tertiary butoxide needs to be carried out under nitrogen atmosphere. Handling of potassium tertiary butoxide on large scale in powder form may lead to flying of the reagent and is dangerous to the operating personnel. These problems of handling can be overcome by using Potassium tertiary butoxide in solution form as the reagent.
  • the improved process for preparation of Losartan Potassium by reacting, in primary alcohol such as methanol, a solution of Potassium tertiary butoxide in tertiary butanol with equimolar quantities of Trityl Losartan is disclosed.
  • a solution of potassium tertiary butoxide in isopropyl alcohol is reacted in methanol with Trityl Losartan.
  • Potassium tertiary butoxide is used as a solution in secondary or tertiary alcohol.
  • a process for the synthesis of Losartan Potassium comprising reacting approximately equimolar quantities of Potassium salts such as potassium tertiary butoxide as a solution in a secondary / tertiary alcohol with Trityl Losartan in methanol; refluxing the reaction mixture to obtain a reaction mass comprising Losartan Potassium; momtoring the completion of reaction using TLC; concentrating the reaction mass to approximately 50 %; cooling the reaction mass to approximately -5° C; distilling out the methanol from the reaction mixture; stripping of methanol from the reaction mixture using solvents like isopropyl alcohol or tetrahydrofuran; maintaining the reaction mass in said solvent for approximately 12 hours at 25 to 30° C; cooling the reaction mixture to 0-5° C; filtering out Losartan potassium; washing with chilled Isopropyl alcohol and drying the Losartan Potassium under vacuum.
  • Potassium salts such as potassium tertiary butoxide as a solution in a secondary / tert
  • the secondary or tertiary alcohol used for the preparation of potassium tertiary butoxide solution is isopropyl alcohol and tertiary butanol.
  • the preferred strength of the potassium tertiary butoxide solution is 15 to 25% (w/v); most preferred strength is 15 to 20% (w/v).
  • potassium salts such as anhydrous potassium carbonate in a primary or secondary alcohol
  • Trityl Losartan is reacted with Trityl Losartan to yield Losartan Potassium in high yields.
  • a process for manufacture of Losartan potassium comprising reacting equimolar quantities of anhydrous alkali metal salt in methanol with approximately 1 mole Trityl Losartan; refluxing the reaction mixture for 10 to 15 hours; monitoring the completion of reaction using TLC; concentrating the reaction mass to approximately 50 %; cooling the reaction mass to approximately -5° C; distilling out the methanol from the reaction mixture; stripping of methanol from the reaction mixture using solvents like isopropyl alcohol or tetrahydrofuran; maintaining the reaction mass in said solvent for approximately 12 hours at 25 to 30° C; cooling the reaction mixture to 0-5° C; filtering out Losartan potassium; washing with chilled Isopropyl alcohol and drying the Losartan Potassium under vacuum.
  • potassium salts used are selected from anhydrous potassium carbonate and potassium bicarbonate.
  • the primary or secondary alcohols u ⁇ ed in the invention as the reaction media includes methanol, ethanol and isopropyl alcohol. This process of replacing potassium tertiary butoxide with these potassium salts has substantial advantages in terms of cost on a manufacturing scale.
  • the Losartan potassium obtained after removal of triphenyl methyl ether was concentrated and the solvent is chased using solvent such as tetrahydrofuran (THF) or a mixture thereof with IPA.
  • THF tetrahydrofuran
  • the THF layer was refluxed for a period of 0.5 - 3 hours followed by cooling of the solution to a temperature of 25 - 30°C and kept at this condition for a period of 10 - 15 hours.
  • the reaction mass was then chilled to a temperature of 0-5°C. There after the precipitated crystals filtered and dried, the crystals are identical with the polymo ⁇ hic Form I of Losartan potassium.
  • the crystal form was identified by differential scanning calorimetry and X -Ray powder diffraction patterns.
  • the polymo ⁇ h Form I was prepared by the following steps comprising reacting Trityl Losartan with equimolar quantity of anhydrous potassium carbonate in methanol; refluxing the resultant mixture for a period of 7 - 12 hours; concentrating methanol to half volume; filtering triphenyl methyl methyl ether; concentrating the methanol mixture to 50% volume; removing residual solvent using solvents like isopropyl alcohol, tetrahydrofuran (THF) or its mixture thereof and keeping the mass at 25-30°C for aging the crystal growth for a period of 10 - 15 hours; chilling the said solvent layer to a temperature of 0-5°C to precipitate the crystals of polymo ⁇ h I and filtering the said precipitated crystals of polymo ⁇ h Form I.
  • THF tetrahydrofuran
  • the process for manufacture of polymo ⁇ h Form I of Losartan potassium comprising dissolving Losartan potassium obtained after detritylation, in solvent tetrahydrofuran or its mixture thereof with solvents such as isopropyl alcohol at reflux; cooling to a temperature of 25-30°C; aging the crystal at this temperature for a period of 7-13 hours and cooling the mass to a temperature of 0-5°C.
  • solvents such as isopropyl alcohol at reflux
  • tetrahydrofuran is used to dissolve Losartan potassium obtained after detritylation in the said manufacturing process of Polymo ⁇ h Form I of Losartan potassium.
  • Losartan potassium polymo ⁇ h Form I was obtained by changing the base to potassium tertiary butoxide in place of potassium carbonate.
  • the reaction mass is then cooled to 0 - 5°C and filtered.
  • the resulting product, Losartan Potassium is then washed with chilled isopropyl alcohol (45 ml.).
  • the final product is dried at 35-50°C under vacuum for 6 hours to remove residual isopropyl alcohol.
  • the percentage yield of Losartan Potassium/orm / is 81%.
  • Isopropyl alcohol (225 ml) is charged, refluxed for 1 hour, cooled and kept for 12 hours at 25-30°C. The reaction mass is then cooled to 0 - 5°C and filtered. The resulting product, Losartan Potassium is then washed with chilled isopropyl alcohol (45 ml). The final product is dried at 35-50°C under vacuum for 6 hours to remove residual isopropyl alcohol. The percentage yield of Losartan Potassium form /is 82%.
  • the reaction mass is then chilled to 0 - 5°C and filtered.
  • the resulting product, Losartan Potassium is then washed with chilled tetrahydrofuran(45 ml).
  • the final product is dried at 35-50°C under vacuum for 6 hours to remove residual tetrahydrofuran.
  • the percentage yield of Losartan Potassium or / is 90 %.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne un procédé amélioré utilisant des alcools primaires, secondaires et tertiaires qui permet une introduction plus sûre du réactif et présente des conditions de réaction plus sûres. L'invention concerne également un procédé de production de losartan potassique en utilisant du sel de métal alcalin tel que le carbonate de potassium. L'invention se rapporte enfin à un procédé de préparation de la forme I polymorphe du losartan potassique.
EP04785921A 2004-01-06 2004-06-15 Procede ameliore de synthese du losartan potassique Withdrawn EP1709034A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN14MU2004 2004-01-06
PCT/IN2004/000169 WO2005066158A2 (fr) 2004-01-06 2004-06-15 Procede ameliore de synthese du losartan potassique

Publications (1)

Publication Number Publication Date
EP1709034A2 true EP1709034A2 (fr) 2006-10-11

Family

ID=34746662

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04785921A Withdrawn EP1709034A2 (fr) 2004-01-06 2004-06-15 Procede ameliore de synthese du losartan potassique

Country Status (2)

Country Link
EP (1) EP1709034A2 (fr)
WO (1) WO2005066158A2 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0736021A4 (fr) * 1993-12-23 1997-04-02 Merck & Co Inc Polymorphes de losartane et procede de preparation de la forme ii du losartane
ES2173433T3 (es) * 1996-10-29 2002-10-16 Merck & Co Inc Procedimiento para la cristalizacion de losartan.
HU222773B1 (hu) * 2000-04-21 2003-10-28 Richter Gedeon Vegyészeti Gyár Rt. Eljárás egy ismert tetrazolszármazék előállítására
EP1294712A1 (fr) * 2001-05-18 2003-03-26 Aurobindo Pharma Limited Procede de cristallisation du losartan potassium
CN1612866A (zh) * 2001-11-14 2005-05-04 特瓦制药工业有限公司 无定形和结晶形的氯沙坦钾及其制备方法
AU2003228767A1 (en) * 2002-04-29 2003-11-17 Teva Pharmaceutical Industries Ltd. Processes for preparing losartan and losartan potassium

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005066158A3 *

Also Published As

Publication number Publication date
WO2005066158A2 (fr) 2005-07-21
WO2005066158A3 (fr) 2005-08-25

Similar Documents

Publication Publication Date Title
JP5535082B2 (ja) ボセンタン、その多形形態及びその塩の合成方法
US10040778B2 (en) Anhydrous lenalidomide form-I
CA2801101C (fr) Procede pour preparer un acide biphenyl-2-ylcarbamique
US11739057B2 (en) Polymorphic forms of Belinostat and processes for preparation thereof
JP2002535315A (ja) テルミサルタンの多形体、その調製方法及び医薬組成物の調製のためのその使用
CA2707334A1 (fr) Procede de preparation ou de purification de l'olmesartan medoxomil
JP2004520446A (ja) ロサルタンカリウムの結晶化方法
EP1274702B1 (fr) Procede de synthese d'un derive connu du tetrazol
JP2004520446A5 (fr)
US20080214637A1 (en) Process for the Synthesis of Tetrazoles
EP1789412A1 (fr) Base d'alfuzosine cristalline
US7345071B2 (en) Process for the synthesis of Losartan potassium
EP1709034A2 (fr) Procede ameliore de synthese du losartan potassique
WO2012103105A1 (fr) Procédés de préparation du raltégravir et de ses intermédiaires dans lesdits procédés
US20130085304A1 (en) Processes for preparation of polymorphic forms of lacosamide
US6916935B2 (en) Losartan potassium synthesis
WO2004087691A1 (fr) Procede de synthese de losartan potassique
KR101184433B1 (ko) 결정형 올메사탄 실렉세틸의 제조방법
WO2024033632A1 (fr) Procédé amélioré de préparation d'analogues de phosphonate antiviraux
EP2022790A1 (fr) Procédé pour la préparation ou la purification d'olmésartan médoxomil
EP1544198B1 (fr) Procédé de synthèse de losartan potassique cristallin
US20100174073A1 (en) Process for the preparation of alfuzosin and salts thereof
JP2010526126A (ja) バルサルタンの製造方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060721

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SAXENA, ASHVINI KUMAR NAND KISHORE

Inventor name: KUMAR, ASHOK

Inventor name: UPARE, ABHAY ATMARAM

Inventor name: NIMBALKAR, MANMOHAN MADHAVRAO

Inventor name: SINGH, RAJESH KUMAR KESHAVA PRASAD

Inventor name: SOUDAGAR, SATISH RAJANIKANT

Inventor name: PANDA, NALINAKSHYA BALARAM

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20070821

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100615